| Property | Value |
|---|
|
?:abstract
|
-
BACKGROUND There remains controversy over the usage of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in patients with coronavirus disease 2019 (COVID-19) given their interaction with the angiotensin converting enzyme-2 (ACE-2) receptor mechanism. OBJECTIVE To investigate the impact of ACEI/ARB on COVID-19 associated disease severity and mortality through a systematic review and meta-analysis of existing literature. METHODS We searched PubMed and CINAHL databases as well as pre-print servers for gray literature regarding studies investigating usage of ACEIs/ARBs in patients with confirmed COVID-19 compared to a control group of COVID-19 patients without ACEI/ARB use. COVID-19 related severity of disease, and death were identified as end points. Pooled odds ratios (OR) and their 95% confidence intervals (CI) were calculated using random-effects model. RESULTS 21 studies were included in the meta-analysis. For mortality with ACEI/ARB use, the pooled odds ratio was 1.29 [0.89-1.87] p=0.18 with heterogeneity of 91%, while the pooled OR for COVID-19 severity was 0.94 [0.59-1.50] p=0.81 with heterogeneity of 89% (Figure2). In combining both mortality and severe disease outcomes, the pooled odds ratio was 1.09 [0.80-1.48] p=0.58 but with heterogeneity of 92%. [Figure: see text]. CONCLUSION use of ACEI/ARB was not associated with increased mortality or severe COVID-19.
|
|
?:creator
|
|
|
?:doi
|
-
10.1080/14779072.2020.1826308
|
|
?:doi
|
|
|
?:journal
|
-
Expert_review_of_cardiovascular_therapy
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers and Outcomes in patients with COVID-19: A Systematic Review and Meta-Analysis.
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}